AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
An overview of which total market fund performed best in 2024, with notes on expense, tracking error, and performance drivers.
28,518 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Bitcoin is pulling back from its peak, a move many investors fear. History, though, suggests cycles, patience, and di...
A fresh memory company touts a coiled-spring architecture to outpace NAND rivals amid AI-driven demand, sparking a co...
Micron Technology presses the AI memory story, delivering strong margins and cloud demand while facing volatility and...
Oil prices climbed amid renewed U.S.-Iran clashes near the Strait of Hormuz, with stock-index futures drifting lower ...
Uniswap community votes on v4 fees and Robinhood Chain expansion, potentially boosting the UNI burn as part of the UN...
Trilogy Metals has fallen hard this week, leaving investors asking whether the downturn is a short-lived pullback or ...
Mortgage rates fall below 6%, giving buyers a clearer affordability path as the spring home-buying season looms. Anal...
Bitcoin failed to clear the $70,000 mark again as heavy selling pressure from large holders weighs on price. Analysts...
Jim Cramer’s take on Power Solutions International’s sharp drop spotlights a potential entry point for data center-re...
A Manhattan class-action accuses Gemini of misrepresenting its growth plan during its September IPO. Shares have fall...
A wave of women is exiting the workforce as caregiving costs climb faster than wages. Experts warn this could herald ...